ライフサイエンスコーパス: blood pressure lowering

1 cardiovascular event rates without lipid or blood pressure lowering.

2 at with losartan monotherapy, independent of blood pressure lowering.

3 kers have vascular protective effects beyond blood pressure lowering.

4 lt of CHF, even in the setting of aggressive blood pressure lowering.

5 ong adults with CKD, 69.5% were eligible for blood pressure lowering according to the 2021 KDIGO guid

6 e vast amount of evidence on the benefits of blood pressure lowering accumulated to date, elevated bl

7 than another and to estimate the additional blood pressure lowering achievable by personalized treat

8 ral bioavailability in rats and demonstrated blood pressure lowering activity in the double-transgeni

9 l dogs to assess its biological actions as a blood pressure-lowering agent and as a natriuretic facto

10 ed-dose combination strategy of at least two blood pressure lowering agents plus a statin (with or wi

11 mised trials from around the world comparing blood pressure-lowering agents in adults with diabetic k

12 s does not support a consistent link between blood pressure lowering and a reduced risk of HFpEF, par

13 isease and Hypertension, a clinical trial of blood pressure lowering and antihypertensive medication

14 tention to optimal secondary prevention with blood pressure lowering and antithrombotic and statin th

15 s a factorial randomized controlled trial of blood pressure lowering and blood glucose control in pat

16 ow-dose triple-pill protocol achieved better blood pressure lowering and control with good tolerabili

17 efforts to restrict salt supply, may achieve blood pressure lowering and deliver health benefits to r

18 Blood pressure lowering and haemostatic treatment minimi

19 ound in the association between differential blood pressure lowering and major cardiovascular events.

20 ss unresolved issues including durability of blood pressure lowering and reduction in antihypertensiv

21 r likelihood of new-onset AF, independent of blood pressure lowering and treatment modality in essent

22 f CV morbidity and mortality, independent of blood pressure lowering and treatment modality in person

23 linical end points, additional to effects of blood pressure lowering and treatment modality.

24 that a novel conjugated oral hBNP possesses blood pressure-lowering and natriuretic actions over a 6

25 es, including glucose lowering, weight loss, blood pressure lowering, and a reduced risk of major adv

26 iovascular outcomes, hypertension, intensive blood pressure lowering, and randomised trials.

27 erapy (polypill) that combines antiplatelet, blood pressure-lowering, and cholesterol-lowering medica

28 eiving uninterrupted treatment with statins, blood pressure-lowering, antidiabetic, and antiplatelet

29 eview focuses on the role of lipid-lowering, blood pressure-lowering, antithrombotic drugs and diet a

30 he Anglo-Scandinavian Cardiac Outcomes Trial Blood Pressure Lowering Arm (ASCOT-BPLA) compared amlodi

31 he Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA) show significan

32 e Anglo-Scandinavian Cardiac Outcomes Trial--Blood Pressure Lowering Arm (ASCOT-BPLA) whose BP remain

33 n (Anglo-Scandinavian Cardiac Outcomes Trial Blood Pressure Lowering Arm [ASCOT-BPLA]).

34 A (Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm).

35 he Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure-Lowering Arm has been extended for up to

36 iting picomolar binding affinity and in vivo blood pressure lowering at pharmaceutically relevant dos

37 ve important mechanisms of action apart from blood pressure lowering but also that effective treatmen

38 Blood pressure lowering by lifestyle modifications and a

39 We assessed intensive blood pressure lowering compared with guideline-recommen

40 combination achieved and maintained greater blood pressure lowering compared with the common strateg

41 t-trial follow-up for a median of 5.9 years (blood-pressure-lowering comparison) or 5.4 years (glucos

42 e randomised controlled trials comparing one blood pressure lowering drug class with a placebo, inact

43 s with a placebo, inactive control, or other blood pressure lowering drug.

44 als evaluating FDC therapy with at least one blood pressure-lowering drug and one lipid-lowering drug

45 rtension from households able to afford four blood pressure-lowering drug classes were more likely to

46 Hg) who were untreated or receiving a single blood pressure-lowering drug.

47 tment with antiplatelet, lipid-lowering, and blood pressure lowering drugs (all p<0.0001).

48 RAS-blockers or other classes of first line blood pressure lowering drugs in COVID-19.

49 h an approach could include the cessation of blood pressure lowering drugs, adoption of lifestyle mea

50 ortant CVD preventive medications, including blood pressure lowering drugs, statins, and aspirin.

51 in random order with 4 different classes of blood pressure-lowering drugs (lisinopril [angiotensin-c

52 -controlled trials of 4 different classes of blood pressure-lowering drugs (thiazides, beta-blockers,

53 were 17,641 participants who were allocated blood pressure-lowering drugs and 6603 who were allocate

54 Hypertension was defined as prescription of blood pressure-lowering drugs as obtained from the natio

55 a quadpill-a single capsule containing four blood pressure-lowering drugs each at quarter-dose (irbe

56 ct from the practical benefits of the use of blood pressure-lowering drugs in preventing headaches an

57 med to investigate the benefits and harms of blood pressure-lowering drugs in this population of pati

58 uded if they were currently taking 2 or more blood pressure-lowering drugs or had severe or uncontrol

59 Our results show that blood pressure-lowering drugs prevent a significant prop

60 Uncertainty exists over whether blood pressure-lowering drugs prevent headache.

61 The availability of two or more classes of blood pressure-lowering drugs was lower in low-income an

62 pressure >/=140/90 mm Hg or those receiving blood pressure-lowering drugs) had a lifetime risk of ov

63 have tested whether a range of antibiotics, blood pressure-lowering drugs, a mast cell stabilizer, a

64 ectiveness of antiplatelets, anticoagulants, blood pressure-lowering drugs, glucose-lowering drugs, o

65 tihypertensive action of diuretics and other blood pressure-lowering drugs.

66 kidney disease comparing orally administered blood pressure-lowering drugs.

67 To prevent stroke most effectively, blood-pressure-lowering drugs should reduce mean blood p

68 A polypill comprising statins, multiple blood-pressure-lowering drugs, and aspirin has been prop

69 y disease) who were receiving at least three blood-pressure-lowering drugs, including a diuretic, at

70 If the blood pressure lowering effect and safety of renal dener

71 hypothalamic NPYergic mechanisms mediate the blood pressure lowering effect of caloric restriction in

72 ypertension in mice and exerts a significant blood pressure lowering effect on preexisting hypertensi

73 r the renal protection, independent from its blood pressure lowering effect, have not yet been fully

74 ses provide robust estimates of the expected blood pressure-lowering effect for any combination of an

75 Finally, fish oil has a mild blood pressure-lowering effect in both normal and mildly

76 The blood pressure-lowering effect of aerobic training is pr

77 hose affecting BNP did not, highlighting the blood pressure-lowering effect of ANP in the general pop

78 A blood pressure-lowering effect of calcium supplementatio

79 e effect of kallistatin yet it abolished the blood pressure-lowering effect of kinin and kallikrein.

80 The blood pressure-lowering effect of SKA-31 suggests KCa3.1

81 confirming that they could contribute to the blood pressure-lowering effect of the WL hydrolysate.

82 sensitive model was inversely related to its blood pressure-lowering effect.

83 iologic effects of angiotensin-(1-7) favor a blood pressure-lowering effect.

84 has a key role in ET's superiority to MT in blood pressure-lowering effect.

85 nction, and fibrosis, despite the absence of blood pressure-lowering effect.

86 le in blood (t(0.5) ~ 18 h), has significant blood-pressure lowering effect, and shows fast recovery

87 ebo-controlled trials probably result from a blood-pressure-lowering effect.

88 new class of direct renin inhibitors exerted blood pressure lowering effects in a hypertensive double

89 ber indicate that the strongest evidence for blood pressure lowering effects is in hypertensive as op

90 r combination treatment resulted in additive blood pressure-lowering effects (clinic systolic blood p

91 Few trials have tested the blood pressure-lowering effects of dietary interventions

92 The selective central blood pressure-lowering effects of nitrite have therapeu

93 It is assumed that the blood pressure-lowering effects of reducing sodium intak

94 e of 80-89 mm Hg to test the feasibility and blood pressure-lowering effects of seven nonpharmacologi

95 Although the blood pressure-lowering effects of sodium-glucose cotran

96 m vegetables and fruit may contribute to the blood pressure-lowering effects of the Dietary Approache

97 However, evidence for blood pressure-lowering effects of vitamin C in clinical

98 n contrast, in monkeys, EGF had dose-related blood pressure-lowering effects only; significant hypote

99 in the renin-angiotensin system, with strong blood pressure-lowering effects that vary in mechanisms

100 The pooled placebo-corrected blood pressure-lowering effects were 5/2 mm Hg and 7/5 m

101 rogramming effects of ARBs while eliminating blood pressure-lowering effects.

102 We investigated the blood-pressure-lowering effects of the new vasodilatory,

103 The aim of the study was to assess the blood pressure lowering efficacy of the dual endothelin

104 nd high intensity, corresponding to systolic blood pressure-lowering efficacy of <10 mm Hg, 10-19 mm

105 We aimed to quantify the blood pressure-lowering efficacy of antihypertensive dru

106 Denervation for Hypertension) confirmed the blood pressure-lowering efficacy of renal denervation ad

107 Blood pressure-lowering efficacy was estimated using fix

108 ave provided proof-of-principle data for its blood pressure-lowering efficacy.

109 rovide biological proof of principle for the blood-pressure-lowering efficacy of renal denervation.

110 In contrast, blood pressure lowering, estimated glomerular filtration

111 The benefit of blood pressure lowering for the prevention of dementia o

112 an event rate of 1.2% per year in intensive blood pressure-lowering group participants, compared wit

113 istent across patient groups, and additional blood pressure lowering had a clear benefit even in pati

114 vity profile and demonstrated robust in vivo blood pressure lowering in a spontaneously hypertensive

115 icyclic thiazepinone, demonstrated excellent blood pressure lowering in a variety of animal models ch

116 Uncertainty persists over the effects of blood pressure lowering in acute intracerebral haemorrha

117 ubstituted azepinone, demonstrated excellent blood pressure lowering in animal models.

118 Some of these may provide potent blood pressure lowering in broad groups of patients, suc

119 Thus, the long-term benefits of blood pressure lowering in early adulthood are promising

120 The net absolute benefits of intensive blood pressure lowering in high-risk individuals are lar

121 lowering compared with guideline-recommended blood pressure lowering in patients treated with altepla

122 monstrated robust diuresis, natriuresis, and blood pressure lowering in preclinical models, with redu

123 geted hemorrhagic shock, icatibant prevented blood pressure lowering in the angiotensin-converting en

124 efit and harm resulting from early intensive blood pressure lowering in this patient group.

125 based renal denervation produced significant blood pressure lowering in treatment-resistant patients

126 are additional benefits from more intensive blood pressure lowering, including for those with systol

127 Blood pressure lowering is an effective strategy for the

128 Blood pressure lowering is an established strategy for p

129 Although intensive blood pressure lowering is safe, the observed reduction

130 Finally, although blood pressure lowering is undoubtedly beneficial, the c

131 se risk in middle-aged people mainly through blood pressure-lowering mechanisms.

132 ertension, smoking, antiplatelet medication, blood pressure lowering medication, lipid lowering medic

133 y, 15.2% (95% CI 13.3-17.1%) reported taking blood pressure-lowering medication).

134 )albuminuria, the use of lipid-modifying and blood pressure-lowering medication, and prior cardiovasc

135 To examine whether treatment with oral blood-pressure-lowering medication or statins influences

136 used any glucose-lowering medication or any blood-pressure-lowering medication were unchanged after

137 ive drugs versus placebo or other classes of blood pressure lowering medications that had at least 10

138 d-lowering (19.2% versus 4.8%; P<0.001), and blood pressure-lowering medications (23.3% versus 12.1%;

139 ation in the proportion of adults in need of blood pressure-lowering medications depending on which h

140 Inconsistent use of blood pressure-lowering medications trended upward from

141 The proportion of adults in need of blood pressure-lowering medications was highest under th

142 Differences in the proportion needing blood pressure-lowering medications were largest in the

143 s, treatment was based on the regular use of blood pressure-lowering medications, and control was def

144 in their definition of who should be offered blood pressure-lowering medications.

145 hoice on the proportion of adults in need of blood pressure-lowering medications.

146 ated patients were taking 2 or more types of blood pressure-lowering medications.

147 ailable were more likely to use at least one blood pressure-lowering medicine (adjusted odds ratio [O

148 classes were more likely to use at least one blood pressure-lowering medicine (adjusted OR 1.42, 95%

149 ountries do not have access to more than one blood pressure-lowering medicine and, when available, th

150 Ensuring access to affordable blood pressure-lowering medicines is essential for contr

151 roportion of households unable to afford two blood pressure-lowering medicines was 31% in low-income

152 0.0001) than were those in communities where blood pressure-lowering medicines were not available.

153 he availability, costs, and affordability of blood pressure-lowering medicines with data recorded fro

154 assess the availability and affordability of blood pressure-lowering medicines, and the association w

155 the highest proportion of adults in need of blood pressure-lowering medicines, whereas the South and

156 vascular disease (a statin, aspirin, and two blood-pressure-lowering medicines) in 23 such countries.

157 The effect of blood pressure lowering might not be evident in specific

158 Anticoagulation reversal, intensive blood pressure lowering, neurosurgery, and access to cri

159 The effect of intensive blood pressure lowering on brain health remains uncertai

160 inine ratio, and intake of glucose-lowering, blood-pressure lowering, or lipid-lowering medication) w

161 ata were pooled to investigate the effect of blood pressure lowering per se on the risk of new-onset

162 e prevention beyond the expected benefits of blood pressure lowering per se.

163 ied and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the preventi

164 ne system inhibiting, cardiac unloading, and blood pressure lowering properties when compared with na

165 s of BTPs points toward antiinflammatory and blood pressure-lowering properties and improvement in pl

166 Its blood pressure-lowering properties were particularly fav

167 ions of the natriuretic peptides, which have blood pressure-lowering properties.

168 Intensive blood pressure lowering provided greater vascular protec

169 control (placebo or less intensive regimen) blood pressure-lowering regimen.

170 Blood pressure lowering significantly reduces vascular r

171 two largest randomised controlled trials of blood pressure lowering strategies in patients with acut

172 nts uncertainty about whether more intensive blood pressure-lowering strategies are associated with g

173 l trial compared the efficacy of 2 different blood pressure-lowering strategies with longitudinal bra

174 These findings emphasise the need for new blood pressure-lowering strategies, and will help to inf

175 al that compared the efficacy of 2 different blood pressure-lowering strategies.

176 assess the efficacy and safety of intensive blood pressure-lowering strategies.

177 No blood pressure-lowering strategy prolonged survival in a

178 Multiple blood pressure-lowering therapies are available but the

179 sive low-density lipoprotein cholesterol and blood pressure lowering therapy slowed disease progressi

180 efficacy and safety of quarter-standard-dose blood pressure-lowering therapy against placebo.

181 We included 1523 adults from TwinsUK not on blood pressure-lowering therapy and without renal impair

182 Blood pressure-lowering therapy is likely to prevent str

183 hat the main driver of clinical benefit from blood pressure-lowering therapy is the magnitude of bloo

184 More intensive blood pressure-lowering therapy might be associated with

185 served among patients originally assigned to blood-pressure-lowering therapy were attenuated but stil

186 Genetically proxied blood pressure lowering through calcium channel blockers

187 In PAD patients with diabetes, intensive blood pressure lowering to a mean of 128/75 mm Hg result

188 aimed to compare the safety and efficacy of blood pressure lowering treatment according to more inte

189 The benefits of blood pressure lowering treatment for prevention of card

190 (target systolic blood pressure <180 mm Hg) blood pressure lowering treatment over 72 h.

191 pressures less than 130 mm Hg and providing blood pressure lowering treatment to individuals with a

192 ve medication treatment was applied from the Blood Pressure Lowering Treatment Trialists Collaboratio

193 between 1973 and 2008, were obtained by the Blood Pressure Lowering Treatment Trialists' Collaborati

194 dy was based on the resource provided by the Blood Pressure Lowering Treatment Trialists' Collaborati

195 The studyThe Blood Pressure Lowering Treatment Trialists' Collaborati

196 All randomised controlled trials of blood pressure lowering treatment were eligible for incl

197 Intensive blood pressure-lowering treatment achieved RR reductions

198 he benefit or risk associated with intensive blood pressure-lowering treatment can be established onl

199 andomisation, patients in the more intensive blood pressure-lowering treatment group had mean blood p

200 w of evidence that the risks and benefits of blood pressure-lowering treatment in acute stroke might

201 s that caution should be taken in the use of blood pressure-lowering treatment in patients with coron

202 n or placebo therapy was not modified by the blood pressure-lowering treatment strategy in the factor

203 Spironolactone was the most effective blood pressure-lowering treatment, throughout the distri

204 ants to more intensive versus less intensive blood pressure-lowering treatment, with different blood

205 been observed in the group receiving active blood-pressure-lowering treatment during the trial were

206 alizations for heart failure, independent of blood pressure lowering, treatment method, and other ris

207 ion and maintained for 24 h with intravenous blood pressure lowering treatments.

208 iovascular disease, a fifth of whom received blood pressure-lowering treatments.

209 the beneficial effects of lipid-reducing and blood pressure-lowering treatments.

210 nalysis, we searched MEDLINE for large-scale blood pressure lowering trials, published between Jan 1,

211 For blood pressure-lowering trials (n=13), 3 were not congru

212 Blood pressure lowering was not significantly associated

213 Serious adverse events associated with blood pressure lowering were only reported by six trials

214 meta-analysis of randomized clinical trials, blood pressure lowering with antihypertensive agents com

215 Blood pressure lowering with antihypertensive agents com

216 ntial implications of this new guideline for blood pressure lowering with antihypertensive medication

217 he physiological mechanisms that account for blood pressure lowering with baroreflex activation and R

218 udies that provide mechanistic insights into blood pressure lowering with baroreflex activation and R

219 s no evidence of an interaction of intensive blood pressure lowering with dose (low vs standard) of a

220 , and if excess adiposity is not alleviated, blood pressure lowering with many antihypertensive drugs

221 ociation of more intensive vs less intensive blood pressure lowering with primary and secondary outco